文献速递头颈外科

头颈癌患者抑郁发生基线特征识别:随机临床试验二次分析

Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2018-01-01

该研究为随机双盲安慰剂对照试验的回顾性二次分析,纳入125例无基线抑郁的II-IV期头颈癌患者,评估治疗期间中重度抑郁发生的相关因素。ROC分析显示基线QIDS-SR评分(AUC 0.816)和初始放疗(AUC 0.681)与抑郁发生相关;基线QIDS-SR阈值2时诊断灵敏度达100%。

要点

  • 基线QIDS-SR评分≥2或可预测头颈癌治疗期间中重度抑郁发生。
  • 初始放疗为基础的治疗与抑郁发生风险相关。
  • 基线QIDS-SR评分≥2的患者可能从药物预防抑郁中获益最多。

核心结论

  • 基线症状和初始放疗为基础的治疗可能与头颈癌患者中重度抑郁发生相关。
  • 基线QIDS-SR评分≥2的患者可能从药物预防抑郁中获益最多。

研究设计与样本

  • 回顾性、事后二次分析,数据来自前瞻性随机双盲安慰剂对照临床试验。
  • 2008年1月至2011年12月于学术和社区三级头颈癌中心筛查患者。
  • 125例可评估的II-IV期头颈癌且无基线抑郁患者,60例随机接受预防性艾司西酞普兰,65例接受安慰剂。

主要发现

  • 可评估的125例患者中,基线QIDS-SR评分的AUC为0.816(95%CI 0.696-0.935),初始放疗为基础治疗的AUC为0.681(95%CI 0.552-0.811)。
  • 基线QIDS-SR阈值2时诊断灵敏度为100%,阈值4时为94%。

关键数值与推荐

  • QIDS-SR评分范围0-27,评分≥11提示中度或以上抑郁。
  • 基线QIDS-SR评分阈值2时识别抑郁风险的诊断灵敏度为100%。

临床怎么用

  • 对头颈癌患者可考虑使用基线QIDS-SR评分识别抑郁高风险者。
  • 基线QIDS-SR评分≥2或初始放疗为基础治疗的患者可考虑药物预防抑郁。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with head and neck cancer (HNC) experience increased risk of depression and compromised quality of life. Identifying patients with HNC at risk of depression can help establish targeted interventions. OBJECTIVE: To identify factors that may be associated with the development of moderate or severe depression during treatment of HNC. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective, ad hoc, secondary analysis of prospectively collected data from a randomized, double-blind, placebo-controlled clinical trial. Patients were screened at academic- and community-based tertiary care HNC centers from January 2008 to December 2011. Of the 125 evaluable patients with stages II through IV HNC but without baseline depression, 60 were randomized to prophylactic antidepressant escitalopram oxalate and 65 to placebo at the time of the initial diagnosis. Data analyses were conducted from May 2016 to April 2017. MAIN OUTCOMES AND MEASURES: Depression outcomes were measured using Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) scores (range, 0-27 with a score of 11 or higher indicative of moderate or greater depression). Factors that may be associated with development of moderate or severe depression were assessed, including patient demographics; cancer site and stage; primary treatment modality (surgery or radiotherapy); history of depression or other psychiatric diagnosis; previous treatment of depression or suicide attempt, family history of depression, suicide, or suicide attempt; and baseline score on the QIDS-SR and clinician-rated QIDS instruments. Participants were stratified by study site, sex, cancer stage (early [stage II] vs advanced [stage III or IV]), primary modality of treatment (radiotherapy with or without chemotherapy vs surgery with or without radiotherapy), and randomization to placebo or escitalopram and balanced within these strata. RESULTS: The mean (SD) age of the 148 patients in the study population was 63.0 (11.9) years; 118 (79.7%) were men, and 143 (96.6%) were white. In the evaluable population of 125 patients, receiver operating characteristic analyses assessing the area under the curve for baseline QIDS-SR score (0.816; 95% CI, 0.696-0.935) and for initial radiotherapy-based treatment (0.681, 95% CI, 0.552-0.811) suggested that these 2 variables were associated with the likelihood of developing moderate or greater depression during the study period among patients who did not receive prophylactic antidepressants. The diagnostic sensitivity for identifying patients at risk of depression using the baseline QIDS-SR score improved to 100% at a threshold of 2 from 94% at a threshold of 4. CONCLUSIONS AND RELEVANCE: Baseline symptoms and initial radiotherapy-based treatment may be associated with development of moderate or greater depression in patients with HNC. Patients with QIDS-SR baseline scores of 2 or higher may benefit the most from pharmacologic prophylaxis of depression.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Panwar A, Rieke K, Burke WJ, et al. Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 30286230. doi:10.1001/jamaoto.2018.2228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。